Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Update

Coya Therapeutics, Inc. (NASDAQ:COYA) was the recipient of a large increase in short interest in May. As of May 31st, there was short interest totalling 207,000 shares, an increase of 20.0% from the May 15th total of 172,500 shares. Currently, 1.6% of the company’s shares are sold short. Based on an average trading volume of 77,000 shares, the short-interest ratio is currently 2.7 days.

Analysts Set New Price Targets

Several research analysts have recently weighed in on COYA shares. Rodman & Renshaw started coverage on Coya Therapeutics in a research report on Thursday. They issued a “buy” rating and a $18.00 price objective for the company. Chardan Capital reaffirmed a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Wednesday, June 5th.

Hedge Funds Weigh In On Coya Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Coya Therapeutics by 772.3% during the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after purchasing an additional 750,338 shares during the last quarter. AIGH Capital Management LLC boosted its stake in shares of Coya Therapeutics by 92.6% in the 4th quarter. AIGH Capital Management LLC now owns 1,031,977 shares of the company’s stock worth $7,381,000 after buying an additional 496,183 shares during the last quarter. Finally, Greenlight Capital Inc. boosted its stake in shares of Coya Therapeutics by 172.2% in the 4th quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company’s stock worth $9,441,000 after buying an additional 805,959 shares during the last quarter. Institutional investors and hedge funds own 39.75% of the company’s stock.

Coya Therapeutics Trading Down 7.5 %

Coya Therapeutics stock traded down $0.58 during midday trading on Friday, reaching $7.20. The stock had a trading volume of 101,247 shares, compared to its average volume of 55,578. Coya Therapeutics has a 12 month low of $3.21 and a 12 month high of $10.69. The company has a market capitalization of $105.26 million, a P/E ratio of -8.47 and a beta of 0.77. The company has a fifty day moving average price of $8.19 and a two-hundred day moving average price of $7.88.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Thursday, May 9th. The company reported ($0.35) EPS for the quarter. The company had revenue of $0.13 million during the quarter. On average, equities research analysts predict that Coya Therapeutics will post -1.3 earnings per share for the current fiscal year.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.